News Pfizer makes first-line case for Tukysa in breast cancer Pfizer's Tukysa looks poised to find a new role as first-line maintenance therapy for HER2-positive metastatic breast cancer.
News Roche delivers its data reveal for adjuvant giredestrant Roche reveals the data that has it excited about giredestrant in early-stage breast cancer, but how might it be positioned versus CDK4/6 inhibitors?
Digital How integrated patient experience platforms are revolutionis... AI-powered integrated platforms offer an elemental shift in the way that clinical trials are conducted.
News ASH: Jaypirca matches Imbruvica in first-line CLL trial Eli Lilly has revealed the data it hopes will take BTK inhibitor Jaypirca into frontline use for chronic lymphocytic leukaemia.
News ASH: FDA okays Gamida aplastic anaemia therapy as data drops The first cell therapy for severe aplastic anaemia – Gamida Cell's Omisirge – has been approved by the FDA.
News ASH: Gilead preps filing for anito-cel on iMMagine-1 data Gilead's Kite unit has showcased three new CAR-T therapies at ASH, headed by multiple myeloma candidate anito-cel, which could launch next year.
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
